STIM Neuronetics

NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024

MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London, England from June 13th-15th. Six posters and one oral presentation will feature data generated utilizing the NeuroStar TMS (transcranial magnetic stimulation) System. In addition, NeuroStar will exhibit at booth #303.

“We are thrilled to present this meaningful evidence at the Clinical TMS Society Annual Meeting and engage with TMS providers and researchers about recent advancements in our field,” said Cory Anderson, Senior Vice President of Research & Development and Clinical Affairs. “Our extensive data and strong clinical presence establish NeuroStar as the leading TMS device, treating the highest number of patients and supporting providers in delivering exceptional patient care in clinical settings.”

The following data will be presented:

When to Hold and When to Fold: Early Prediction of Nonresponse to Transcranial Magnetic Stimulation in Major Depressive Disorder

  • Presenter: Dr. Harold Sackeim, Professor in Psychiatry and Radiology at Columbia University
  • Overview: In the poster and oral presentation, Dr. Sackeim will explain how early improvement reliably predicts potential responders to treatment; however, the absence of such improvement does not reliably forecast non-response.
  • Presentation Date: June 14th at 2:45 PM BST

The Impact of Treatment Gaps on Effectiveness of Transcranial Magnetic Stimulation in MDD

  • Presenter: Dr. Linda Carpenter, Professor of Psychiatry and Human Behavior at Brown University
  • Overview: Dr. Carpenter will present data regarding the impact of deviations to the established TMS treatment timing on treatment effectiveness.
  • Presentation Date: June 14th at 4:00 PM BST

Accelerated Transcranial Magnetic Stimulation: Preliminary Efficacy Findings Using a Pragmatic Tool

  • Presented by: Sonder Behavioral Health & Wellness, Minnetonka, Minnesota
  • Overview: This study will showcase feasibility, safety, and efficacy results using NeuroStar with a pragmatic accelerated TMS protocol without the need for neuroimaging.
  • Presentation Date: June 14th at 4:00 PM BST

Effectiveness of TMS for Adolescents and Young Adult Real World Outcomes in Patients with Major Depressive Disorder

  • Presenter: Dr. Paul E. Croarkin, Associate Professor of Psychiatry and Psychology, Division Chair, Child and Adolescent Psychiatry, Mayo Clinic College of Medicine and Science
  • Overview: Dr. Croarkin will discuss data that led to NeuroStar's latest FDA clearance to treat adolescents as a first-line, adjunct treatment for major depressive disorder (MDD).
  • Presentation Date: June 14th at 4:00 PM BST

Sensitivity of the PHQ-9 and QIDS-SR16 to the Therapeutic Effects of TMS in Major Depressive Disorder

  • Presenter: Dr. Kenneth Pages, Medical Director of TMS of South Tampa
  • Overview: Dr. Pages will contrast the Patient Health Questionnaire-9 (PHQ-9) and the Quick Inventory of Depressive Symptomatology (QIDS-SR16) regarding each scale’s sensitivity to detection of symptom changes in patients with MDD.
  • Presentation Date: June 14th at 4:00 PM BST

Symptom Profiles Before and After TMS in Major Depressive Disorder

  • Presenter: Dr. Todd Hutton, Chief Medical Director at Southern California TMS Center
  • Overview: Dr. Hutton will identify the impact of TMS on individual symptom domains of MDD utilizing both the PHQ-9 and QIDS-SR16.
  • Presentation Date: June 14th at 4:00 PM BST

For more information about NeuroStar TMS Therapy, please visit .

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit .

Media Contact:

EvolveMKD

646.517.4220



EN
13/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducem...

 PRESS RELEASE

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Socie...

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two signi...

 PRESS RELEASE

Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market op...

 PRESS RELEASE

Neuronetics Launches First Inaugural National TMS Therapy Awareness Da...

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, and non-drug treatment for depression MALVERN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision ...

 PRESS RELEASE

Neuronetics Reports First Quarter 2025 Financial and Operating Results

Neuronetics Reports First Quarter 2025 Financial and Operating Results MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025. First Quarter 2025 Highlights First quarter 2025 revenue of $32.0 million, an 84% incr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch